Generation and preclinical characterization of a novel bispecific CD19-TCRgammadelta antibody for the treatment of B cell acute lymphoblastic leukemia
In summary, the selective activation of Vγ9dδ T cells using our novel CD19xγδ bsAb constitutes a promising immunotherapeutic approach for the treatment of B-ALL. Our results warrant further clinical evaluation especially in patients with minimal residual disease after aSCT or CD3-directed bsAb therapy.
Authors
- Fabian Vogt
- Martin Pflügler
- Sebastian Hörner (ORCID: https://orcid.org/0000-0002-8023-4258)
- Joseph Kauer (ORCID: https://orcid.org/0000-0003-1632-0167)
- Carsten Müller-Tidow
- Gundram Jung
- Simon Raffel
- Valentin Schmidt
- Helmut R. Salih
Institutions
- Heidelberg University (DE)
- University Hospital Heidelberg (DE)
- German Center for Infection Research (DE)
- Guided Therapeutics (United States) (US)
- University of Tübingen (DE)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-02-27
- DOI
- https://doi.org/10.3389/fimmu.2026.1728424
- Primary Topic
- Acute Lymphoblastic Leukemia research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Wilhelm Sander-Stiftung
- Deutsche Forschungsgemeinschaft
- Eberhard Karls Universität Tübingen
- Deutsche Krebshilfe